- Featured Product
- KD/KO Validated
BRCA2 Polyklonaler Antikörper
BRCA2 Polyklonal Antikörper für ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human
Anwendung
WB, IHC, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 19791-1-AP
Synonyme
Galerie der Validierungsdaten
Geprüfte Anwendungen
Empfohlene Verdünnung
Anwendung | Verdünnung |
---|---|
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Veröffentlichte Anwendungen
KD/KO | See 1 publications below |
WB | See 12 publications below |
IHC | See 3 publications below |
Produktinformation
19791-1-AP bindet in WB, IHC, ELISA BRCA2 und zeigt Reaktivität mit human
Getestete Reaktivität | human |
In Publikationen genannte Reaktivität | human |
Wirt / Isotyp | Kaninchen / IgG |
Klonalität | Polyklonal |
Typ | Antikörper |
Immunogen | Peptid |
Vollständiger Name | breast cancer 2, early onset |
Berechnetes Molekulargewicht | 384 kDa |
GenBank-Zugangsnummer | NM_000059 |
Gene symbol | BRCA2 |
Gene ID (NCBI) | 675 |
Konjugation | Unkonjugiert |
Form | Liquid |
Reinigungsmethode | Antigen-Affinitätsreinigung |
Lagerungspuffer | PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3. |
Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).
Protokolle
Produktspezifische Protokolle | |
---|---|
WB protocol for BRCA2 antibody 19791-1-AP | Protokoll herunterladen |
Standard-Protokolle | |
---|---|
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
Species | Application | Title |
---|---|---|
Nucleic Acids Res LncRNA lnc-RI regulates homologous recombination repair of DNA double-strand breaks by stabilizing RAD51 mRNA as a competitive endogenous RNA. | ||
Int J Biol Macromol Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation | ||
Elife LIN37-DREAM prevents DNA end resection and homologous recombination at DNA double-strand breaks in quiescent cells | ||
J Med Chem Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA | ||
Pharmacol Res FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. | ||
Mol Cancer The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy.
|